Logo-bi
Original Research
Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi* ORCID
Bioimpacts. 2019;9(1): 45-56. doi: 10.15171/bi.2019.06
PMCID: PMC6378095     PMID: 30788259     Scopus ID: 85060470196    
Using immunoinformatic tools, a multi-epitope peptide vaccine (consisting of CD8+cytotoxic T lymphocytes epitopes, helper epitopes and adjuvant) was designed to combat the triple-negative breast cancer. The vaccine showed acceptable immunogenicity and potential to stimulate both cellular and humoral immune responses.
Original Research
Ysrafil Ysrafil* ORCID, Zulfiayu Sapiun ORCID, Indwiani Astuti ORCID, Mohammad Anas Anasiru, Nangsih Sulastri Slamet ORCID, Hartati Hartati ORCID, Fadli Husain, Sukmawati Ahmad Damiti ORCID
BioImpacts. 2022;12(4): 359-370. doi: 10.34172/bi.2022.23769
PMCID: PMC9376164     PMID: 35975206     Scopus ID: 85138027836    
The two designed and constructed multiepitope vaccine have good characteristics and may have the potential to activate humoral and cellular immune responses against SARS-CoV-2. Further research is worth considering to confirm the findings of this study.
Original Article
Maryam Rezaei ORCID, Mehri Habibi, Parasoo Ehsani, Mohammad Reza Asadi Karam*, Saeid Bouzari* ORCID
Bioimpacts. 2024;14(1): 27513. doi: 10.34172/bi.2023.27513
PMCID: PMC10844585     PMID: 38327629